Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GR1802 injection plus background therapy in adolescents with seasonal allergic rhinitis
CTR20253870Phase 3Active
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in seasonal allergic rhinitis (SAR), sponsored by Zhixiang Jintai. Started Mar 2026; status: active.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20253870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253870.